AIM ImmunoTech Inc (AIM) USD0.001
Sell:$8.50Buy:$8.80
$0.36
(3.93%)
- This stock can be held in a
Stocks and Shares ISA$0.36
(3.93%)$0.36
(3.93%)Company Information
About this company
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Key people
Key facts
- EPICAIM
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS00901B3033
- Market cap$6.99m
- Employees21
- Shares in issue764,238.00
- ExchangeNyse American LLC
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.